Public information presented according to the provisions of Directive 2001/18/EC (related to GAd20)
File:
Trial reference:
Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, with pembrolizumab, in Patients with Unresectable Stage III / IV Cutaneous Melanoma and with Stage IV NSCLC
Doc type: